Nicole Waalders

Nicole Waalders

Auto-generated profile, based on publicly available information

Nicole Waalders

Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2020 in Critical Care
Verified
Journal Article
Open access
PDF file
EKEmma J. Kooistra
Emma J. Kooistra
NWNicole J. B. Waalders
Nicole J. B. Waalders
IGInge Grondman
Inge Grondman
Nico JanssenNico Janssen
Nico Janssen
ANAline H. de Nooijer
Aline H. de Nooijer
PPPeter Pickkers
Peter Pickkers
Background: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation. Methods: In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment. Results: Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) (p = 0.0002), ferritin (p = 0.009), and temperature (p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature (p = 0.03), white blood cell counts (p = 0.02), and plasma levels of ferritin (p = 0.003), procalcitonin (p = 0.001), creatinine (p = 0.01), and bilirubin (p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results. Conclusions: Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.

8 August 2022 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
AJAron Jansen
Aron Jansen
NBNiklas Bruse
Niklas Bruse
NWNicole Waalders
Nicole Waalders
JGJelle Gerretsen
Jelle Gerretsen
DRDaniëlle Rijbroek
Daniëlle Rijbroek
MKMatthijs Kox
Matthijs Kox
Cytokine production by ex vivo (EV)-stimulated leukocytes is commonly used to gauge immune function and frequently proposed to guide immunomodulatory therapy. However, whether EV cytokine production capacity accurately reflects the in vivo (IV) immune status is largely unknown. We investigated relationships between EV monocyte cytokine responses and IV cytokine responses in a large cohort of healthy volunteers using a highly standardized IV model of short-lived LPS-induced systemic inflammation, which captures hallmarks of both hyperinflammation and immunological tolerance. Therefore, 110 healthy volunteers were intravenously challenged with 1 ng/kg LPS twice: on day 0 to determine the extent of the IV (hyper)inflammatory response and on day 7 to determine the degree of IV endotoxin tolerance. Baseline EV monocyte cytokine production capacity was assessed prior to LPS administration. Short-term and long-term EV tolerance was assessed in monocytes isolated 4 h and 7 days after LPS administration, respectively. No robust correlations were observed between baseline EV cytokine production capacity and IV cytokine responses following LPS administration. However, highly robust inverse correlations were observed between IV cytokine responses and EV cytokine responses of monocytes isolated 4 h after IV LPS administration. No correlations between IV and EV tolerance were found. In conclusion, attenuated EV cytokine production capacity reflects ongoing IV inflammation rather than immune suppression. Results of EV assays should be interpreted with caution at the risk of improper use of immuno­stimulatory drugs.

25 June 2026 in Journal of Innate Immunity
Verified
Journal Article
Open access
SBSuzanne H. Bongers
Suzanne H. Bongers
BJBernard N. Jukema
Bernard N. Jukema
AJAron Jansen
Aron Jansen
DLDirk van Lier
Dirk van Lier
NWNicole Waalders
Nicole Waalders
NVNienke Vrisekoop
Nienke Vrisekoop
Introduction: During acute inflammation, such as experimental human endotoxemia, circulating neutrophil counts initially decrease followed by pronounced neutrophilia. Banded (CD16dim/CD62Lbright) and hypersegmented (CD16bright/CD62Ldim) neutrophils, which are absent in the blood during homeostasis, are rapidly mobilized. Banded and mature neutrophils are thought to be recruited from the bone marrow, while the origin of hypersegmented neutrophils remains disputed and underlying recruitment mechanisms remain to be established. Methods: Fifteen volunteers received an intravenous bolus of bacterial lipopolysaccharide followed by continuous infusion for 3 hours. Seven were randomly assigned to additional cytokine adsorption therapy, enabling analysis of neutrophil subsets across a broad range of circulating cytokine concentrations. Blood samples were obtained at baseline and 3 hours post-LPS bolus to assess neutrophil subset quantities, neutrophil surface activation markers, and plasma cytokine levels. Results: Circulating concentrations of pro-inflammatory cytokines (TNF, IL-6, IL-8, MIP-1α, and MCP-1) were negatively associated with circulating mature and banded neutrophil numbers, suggesting a role for these cytokines in their migration. The absence of a correlation between plasma cytokines with hypersegmented neutrophils indicates an alternative mobilization signal. In contrast to cell numbers, neutrophil activation markers positively correlated with concentrations of the various pro-inflammatory cytokines indicating involvement of cytokines in neutrophil activation. Conclusion: Circulating cytokines appear to be key drivers of mature and banded neutrophil migration whereas this complex signal does not influence the abundance of CD62Ldim cells in peripheral blood.